8-K filing — NRX Pharmaceuticals, Inc. (NRXP)
Filed: 2026-10-16 AccNo: 0001437749-26-032828 Size: 174 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
NRx Pharmaceuticals Announces FDA Receipt Of DISCIPLINE REVIEW LETTER For Changes To Submitted Label For Preservative-Free Ketamine Product Ahead Of Nov. 10
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx" or "the Company"), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $49 to $50.
NRx Pharma’s NRx Defense Systems Announces Award Of Initial $11M Contract Issued By Defense Advanced Research Projects Agency